-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Guide: The vaccine is a biological product for prevention and is intended to be used mainly for the prevention of new coronavirus pneumonia in people aged 18 and over. on July 16,
, Fosun Pharma announced that shanghai Fosun Pharmaceutical Industry Development Co., Ltd., a controlling subsidiary of the company, had received approval from the State Drug Administration for its new approved coronavirus mRNA vaccine (BNT162b1) for the prevention of new coronavirus pneumonia.
Fosun Pharmaceuticals industry intends to conduct Phase I clinical trials of the vaccine in China (excluding Hong Kong, Macao and Taiwan, the same below) after the conditions are met.
announced that fosun Pharmaceutical Industry in March 2020 by the German BioNTechSE authorized, in the region (i.e. Chinese mainland and Hong Kong, Macao and Taiwan, the same below) exclusive development, commercialization based on its proprietary mRNA technology platform developed for the new coronavirus vaccine products, BioNTech as the right person in the region.
the vaccine is a biological product for prevention and is intended to be used mainly for the prevention of new coronavirus pneumonia in people aged 18 and over.
as of the date of this announcement, the vaccine is in Phase I clinical trials in Germany and the United States, respectively, and no preventive vaccine developed on the mRNA technology platform has been approved for market worldwide.
as of June 2020, the Group (i.e., the Company and its controlling subsidiaries/units) has invested approximately RMB14.06 million (unaudited; including licensing fees) in research and development of the vaccine at this stage.
.